Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions
Marjolein de Bruin‐Weller(Netherlands Center for Occupational Diseases), Stephan Weidinger(University Hospital Schleswig-Holstein), Daphne S. Bakker(Utrecht University), Roselie Achten(Utrecht University), Celeste M. Boesjes(University Medical Center Utrecht), Marlies de Graaf(University Medical Center Utrecht), Alan D. Irvine(Trinity College Dublin), Lisa A. Beck(University of Rochester Medicine), Christian Vestergaard(Aarhus University), Femke van Wijk(Utrecht University)
Cited by 13
Related Papers
Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report
|Journal of Allergy and Clinical Immunology|2010|2.3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Atopic dermatitis
|Nature Reviews Disease Primers|2018|1.5k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
|New England Journal of Medicine|2014|1.4k